{"entity":{"type":"insider","cik":"0001341382","url":"/insider/0001341382","json_url":"/insider/0001341382.json","name":"Topper James N","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":968,"n_filings":75,"first":"2005-12-14","last":"2025-09-30","span_basis":"filed_date"},"name_variants":[{"name":"Topper James N","source":"filing","n_filings":75,"first_seen":"2005-12-14","last_seen":"2025-09-30"}],"transactions":[{"id":5072229,"accession":"0001231919-25-000267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000267","line_url":"/filing/0001231919-25-000267#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHMLS X, L.P.; Frazier Life Sciences X, L.P.; Topper James N; FHMLS X, L.L.C.","owner_display_name":"FHMLS X, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":666666.0,"shares_display":"666,666","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":11999988.0,"total_display":"11,999,988.00","total_whole":"11,999,988","shares_owned_after":5219440.0,"shares_owned_after_display":"5,219,440","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-26","filed_date":"2025-09-30","scope":"insider"},{"id":4587569,"accession":"0001341382-25-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001341382-25-000007","line_url":"/filing/0001341382-25-000007#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":660.0,"shares_display":"660","price_per_share":23.6953,"price_display":"23.70","price_state":"stated","total_value":15638.898,"total_display":"15,638.90","total_whole":"15,639","shares_owned_after":3028524.0,"shares_owned_after_display":"3,028,524","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-15","filed_date":"2025-09-17","scope":"insider"},{"id":4055077,"accession":"0001415889-25-024111","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-024111","line_url":"/filing/0001415889-25-024111#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1260.0,"shares_display":"1,260","price_per_share":24.99,"price_display":"24.99","price_state":"stated","total_value":31487.4,"total_display":"31,487.40","total_whole":"31,487","shares_owned_after":3027864.0,"shares_owned_after_display":"3,027,864","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-10","scope":"insider"},{"id":4358821,"accession":"0001415889-25-021660","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-021660","line_url":"/filing/0001415889-25-021660#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":471.0,"shares_display":"471","price_per_share":23.9787,"price_display":"23.98","price_state":"stated","total_value":11293.9677,"total_display":"11,293.97","total_whole":"11,294","shares_owned_after":3026604.0,"shares_owned_after_display":"3,026,604","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-11","filed_date":"2025-08-13","scope":"insider"},{"id":4589908,"accession":"0001415889-25-018316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-018316","line_url":"/filing/0001415889-25-018316#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1260.0,"shares_display":"1,260","price_per_share":18.2632,"price_display":"18.26","price_state":"stated","total_value":23011.632,"total_display":"23,011.63","total_whole":"23,012","shares_owned_after":3026133.0,"shares_owned_after_display":"3,026,133","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-25","filed_date":"2025-06-26","scope":"insider"},{"id":4589905,"accession":"0001415889-25-018316","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-018316","line_url":"/filing/0001415889-25-018316#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2520.0,"shares_display":"2,520","price_per_share":18.4343,"price_display":"18.43","price_state":"stated","total_value":46454.436,"total_display":"46,454.44","total_whole":"46,454","shares_owned_after":3024873.0,"shares_owned_after_display":"3,024,873","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-24","filed_date":"2025-06-26","scope":"insider"},{"id":4176115,"accession":"0001415889-25-017693","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-017693","line_url":"/filing/0001415889-25-017693#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8584.0,"shares_display":"8,584","price_per_share":19.4992,"price_display":"19.50","price_state":"stated","total_value":167381.1328,"total_display":"167,381.13","total_whole":"167,381","shares_owned_after":3022153.0,"shares_owned_after_display":"3,022,153","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-18","scope":"insider"},{"id":5154506,"accession":"0001415889-25-014428","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-014428","line_url":"/filing/0001415889-25-014428#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3780.0,"shares_display":"3,780","price_per_share":3.8649,"price_display":"3.86","price_state":"stated","total_value":14609.322,"total_display":"14,609.32","total_whole":"14,609","shares_owned_after":59403.0,"shares_owned_after_display":"59,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-21","filed_date":"2025-05-23","scope":"insider"},{"id":4319650,"accession":"0001415889-25-013134","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-013134","line_url":"/filing/0001415889-25-013134#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6300.0,"shares_display":"6,300","price_per_share":3.3205,"price_display":"3.32","price_state":"stated","total_value":20919.15,"total_display":"20,919.15","total_whole":"20,919","shares_owned_after":55623.0,"shares_owned_after_display":"55,623","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-14","filed_date":"2025-05-15","scope":"insider"},{"id":4319643,"accession":"0001415889-25-013134","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-013134","line_url":"/filing/0001415889-25-013134#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1120.0,"shares_display":"1,120","price_per_share":3.1637,"price_display":"3.16","price_state":"stated","total_value":3543.344,"total_display":"3,543.34","total_whole":"3,543","shares_owned_after":49323.0,"shares_owned_after_display":"49,323","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-13","filed_date":"2025-05-15","scope":"insider"},{"id":4146467,"accession":"0001415889-25-012770","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-012770","line_url":"/filing/0001415889-25-012770#line-3","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12601.0,"shares_display":"12,601","price_per_share":3.0395,"price_display":"3.04","price_state":"stated","total_value":38300.7395,"total_display":"38,300.74","total_whole":"38,301","shares_owned_after":48203.0,"shares_owned_after_display":"48,203","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-12","filed_date":"2025-05-13","scope":"insider"},{"id":4146465,"accession":"0001415889-25-012770","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012770","line_url":"/filing/0001415889-25-012770","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35602.0,"shares_display":"35,602","price_per_share":3.2193666928824225,"price_display":"3.22","price_state":"stated","total_value":114615.893,"total_display":"114,615.89","total_whole":"114,616","shares_owned_after":33376.0,"shares_owned_after_display":"33,376","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-09","filed_date":"2025-05-13","scope":"insider","n_lines":2},{"id":5038908,"accession":"0001415889-25-009198","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-009198","line_url":"/filing/0001415889-25-009198#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1135.0,"shares_display":"1,135","price_per_share":22.4851,"price_display":"22.49","price_state":"stated","total_value":25520.5885,"total_display":"25,520.59","total_whole":"25,521","shares_owned_after":3013569.0,"shares_owned_after_display":"3,013,569","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-26","filed_date":"2025-03-28","scope":"insider"},{"id":5193280,"accession":"0001415889-25-007263","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-007263","line_url":"/filing/0001415889-25-007263#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4005.0,"shares_display":"4,005","price_per_share":21.0245,"price_display":"21.02","price_state":"stated","total_value":84203.1225,"total_display":"84,203.12","total_whole":"84,203","shares_owned_after":3012434.0,"shares_owned_after_display":"3,012,434","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-04","filed_date":"2025-03-06","scope":"insider"},{"id":2037681,"accession":"0000950170-24-107536","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-107536","line_url":"/filing/0000950170-24-107536#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHMLS X, L.L.C.; FHMLS X, L.P.; Frazier Life Sciences X, L.P.; Topper James N","owner_display_name":"FHMLS X, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":4552774.0,"shares_owned_after_display":"4,552,774","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":2929138,"accession":"0001415889-24-011664","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-011664","line_url":"/filing/0001415889-24-011664#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"ALPINE IMMUNE SCIENCES, INC.","issuer_ticker":"ALPN","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19.0,"shares_display":"19","price_per_share":64.57,"price_display":"64.57","price_state":"stated","total_value":1226.83,"total_display":"1,226.83","total_whole":"1,227","shares_owned_after":2829347.0,"shares_owned_after_display":"2,829,347","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-25","filed_date":"2024-04-29","scope":"insider"},{"id":2278334,"accession":"0001415889-24-010490","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-010490","line_url":"/filing/0001415889-24-010490#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"HilleVax, Inc.","issuer_ticker":"HLVX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHMLS X, L.L.C.; Heron Patrick J; FHMLS X, L.P.; Topper James N","owner_display_name":"FHMLS X, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8850.0,"shares_display":"8,850","price_per_share":14.5,"price_display":"14.50","price_state":"stated","total_value":128325.0,"total_display":"128,325.00","total_whole":"128,325","shares_owned_after":8544187.0,"shares_owned_after_display":"8,544,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-04","filed_date":"2024-04-08","scope":"insider"},{"id":2069462,"accession":"0001415889-24-009330","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-009330","line_url":"/filing/0001415889-24-009330#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8429.0,"shares_display":"8,429","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":181223.5,"total_display":"181,223.50","total_whole":"181,224","shares_owned_after":3008429.0,"shares_owned_after_display":"3,008,429","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-26","filed_date":"2024-03-28","scope":"insider"},{"id":8156001,"accession":"0001209191-23-053662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-053662","line_url":"/filing/0001209191-23-053662#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences VIII, L.P.; Topper James N; FHM LIFE SCIENCES VIII, L.P.; Heron Patrick J; FHM LIFE SCIENCES VIII, L.L.C.","owner_display_name":"Frazier Life Sciences VIII, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80000.0,"shares_display":"80,000","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":8764232.0,"shares_owned_after_display":"8,764,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-24","filed_date":"2023-10-26","scope":"insider"},{"id":6612968,"accession":"0001209191-22-045014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-045014","line_url":"/filing/0001209191-22-045014#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.; FHM LIFE SCIENCES VIII, L.P.; Heron Patrick J; Topper James N","owner_display_name":"Frazier Life Sciences VIII, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":8684232.0,"shares_owned_after_display":"8,684,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-05","filed_date":"2022-08-09","scope":"insider"},{"id":6670086,"accession":"0000899243-22-016310","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-016310","line_url":"/filing/0000899243-22-016310#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"HilleVax, Inc.","issuer_ticker":"HLVX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Heron Patrick J; FHMLS X, L.P.; Frazier Life Sciences X, L.P.; Topper James N; FHMLS X, L.L.C.","owner_display_name":"Heron Patrick J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1764706.0,"shares_display":"1,764,706","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":30000002.0,"total_display":"30,000,002.00","total_whole":"30,000,002","shares_owned_after":8535337.0,"shares_owned_after_display":"8,535,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-03","filed_date":"2022-05-03","scope":"insider"},{"id":6918554,"accession":"0001209191-22-009821","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-009821","line_url":"/filing/0001209191-22-009821#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"ALPINE IMMUNE SCIENCES, INC.","issuer_ticker":"ALPN","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Topper James N; Frazier Life Sciences VIII, L.P.; Heron Patrick J; FHM LIFE SCIENCES VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.","owner_display_name":"Topper James N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":112665.0,"shares_display":"112,665","price_per_share":7.1006,"price_display":"7.10","price_state":"stated","total_value":799989.099,"total_display":"799,989.10","total_whole":"799,989","shares_owned_after":1484115.0,"shares_owned_after_display":"1,484,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-11","filed_date":"2022-02-15","scope":"insider"},{"id":2922691,"accession":"0001104659-20-134761","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-134761","line_url":"/filing/0001104659-20-134761#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Frazier Lifesciences Acquisition Corp","issuer_ticker":"FLAC","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHMLS X, L.L.C.; Frazier Lifesciences Sponsor LLC; Topper James N; Heron Patrick J; Frazier Life Sciences X, L.P.; FHMLS X, L.P.","owner_display_name":"FHMLS X, L.L.C.","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":"Chief Executive Officer","security_title":"Class A Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":1000000.0,"shares_owned_after_display":"1,000,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-11","filed_date":"2020-12-11","scope":"insider"},{"id":3047194,"accession":"0001209191-20-055425","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-055425","line_url":"/filing/0001209191-20-055425#line-3","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Tarsus Pharmaceuticals, Inc.","issuer_ticker":"TARS","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences IX, L.P.; FHMLS IX, L.P.; Topper James N; Heron Patrick J; FHMLS IX, L.L.C.","owner_display_name":"Frazier Life Sciences IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1917157.0,"shares_owned_after_display":"1,917,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-20","scope":"insider"},{"id":2334556,"accession":"0001209191-20-015666","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-015666","line_url":"/filing/0001209191-20-015666#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Topper James N; FHMLS IX, L.L.C.; Frazier Life Sciences IX, L.P.; FHMLS IX, L.P.","owner_display_name":"Topper James N","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":550000.0,"shares_display":"550,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":9900000.0,"total_display":"9,900,000.00","total_whole":"9,900,000","shares_owned_after":5009219.0,"shares_owned_after_display":"5,009,219","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-03","filed_date":"2020-03-03","scope":"insider"},{"id":2090194,"accession":"0001209191-20-007100","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-007100","line_url":"/filing/0001209191-20-007100#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHM LIFE SCIENCES VIII, L.P.; Topper James N; FHM LIFE SCIENCES VIII, L.L.C.; Frazier Life Sciences VIII, L.P.","owner_display_name":"FHM LIFE SCIENCES VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":8500000.0,"total_display":"8,500,000.00","total_whole":"8,500,000","shares_owned_after":10542790.0,"shares_owned_after_display":"10,542,790","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider"},{"id":2576701,"accession":"0001209191-20-003162","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-003162","line_url":"/filing/0001209191-20-003162#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Heron Patrick J; Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.; Topper James N; FHM LIFE SCIENCES VIII, L.P.","owner_display_name":"Heron Patrick J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":5.0002,"price_display":"5.00","price_state":"stated","total_value":250010.0,"total_display":"250,010.00","total_whole":"250,010","shares_owned_after":1299953.0,"shares_owned_after_display":"1,299,953","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-09","filed_date":"2020-01-13","scope":"insider"},{"id":8601348,"accession":"0001209191-19-054525","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-054525","line_url":"/filing/0001209191-19-054525#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHMLS IX, L.P.; Topper James N; FHMLS IX, L.L.C.; Frazier Life Sciences IX, L.P.; Heron Patrick J","owner_display_name":"FHMLS IX, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1052631.0,"shares_display":"1,052,631","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":19999989.0,"total_display":"19,999,989.00","total_whole":"19,999,989","shares_owned_after":7284269.0,"shares_owned_after_display":"7,284,269","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-29","filed_date":"2019-10-30","scope":"insider"},{"id":8027525,"accession":"0001209191-19-043024","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-043024","line_url":"/filing/0001209191-19-043024#line-2","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences IX, L.P.; Topper James N; FHMLS IX, L.P.; FHMLS IX, L.L.C.","owner_display_name":"Frazier Life Sciences IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6750000.0,"total_display":"6,750,000.00","total_whole":"6,750,000","shares_owned_after":3566912.0,"shares_owned_after_display":"3,566,912","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-22","filed_date":"2019-07-24","scope":"insider"},{"id":8230906,"accession":"0001209191-19-004779","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-004779","line_url":"/filing/0001209191-19-004779#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"ALPINE IMMUNE SCIENCES, INC.","issuer_ticker":"ALPN","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":372439.0,"shares_display":"372,439","price_per_share":5.37,"price_display":"5.37","price_state":"stated","total_value":1999997.43,"total_display":"1,999,997.43","total_whole":"1,999,997","shares_owned_after":2571450.0,"shares_owned_after_display":"2,571,450","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-18","filed_date":"2019-01-22","scope":"insider"},{"id":6913425,"accession":"0001209191-18-053540","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-053540","line_url":"/filing/0001209191-18-053540#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":375887.0,"shares_display":"375,887","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":5638305.0,"total_display":"5,638,305.00","total_whole":"5,638,305","shares_owned_after":1349953.0,"shares_owned_after_display":"1,349,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-28","filed_date":"2018-10-02","scope":"insider"},{"id":6495912,"accession":"0001104659-18-042310","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-18-042310","line_url":"/filing/0001104659-18-042310#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":3190079.0,"shares_owned_after_display":"3,190,079","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"},{"id":4180706,"accession":"0000899243-17-025455","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-17-025455","line_url":"/filing/0000899243-17-025455#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Allena Pharmaceuticals, Inc.","issuer_ticker":"ALNA","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":7000000.0,"total_display":"7,000,000.00","total_whole":"7,000,000","shares_owned_after":3330373.0,"shares_owned_after_display":"3,330,373","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-06","filed_date":"2017-11-06","scope":"insider"},{"id":5251173,"accession":"0001209191-17-011565","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-011565","line_url":"/filing/0001209191-17-011565#line-1","is_derivative":false,"issuer_cik":"0001290149","issuer_name":"Sierra Oncology, Inc.","issuer_ticker":"SRRA","issuer_name_source":null,"issuer_url":"/issuer/0001290149","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5925926.0,"shares_display":"5,925,926","price_per_share":1.35,"price_display":"1.35","price_state":"stated","total_value":8000000.1,"total_display":"8,000,000.10","total_whole":"8,000,000","shares_owned_after":5925926.0,"shares_owned_after_display":"5,925,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-02-14","filed_date":"2017-02-16","scope":"insider"},{"id":4859385,"accession":"0001209191-17-006406","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-17-006406","line_url":"/filing/0001209191-17-006406","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"ANAPTYSBIO INC","issuer_ticker":"ANAB","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6000000.0,"total_display":"6,000,000.00","total_whole":"6,000,000","shares_owned_after":1045031.0,"shares_owned_after_display":"1,045,031","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-31","filed_date":"2017-01-31","scope":"insider","n_lines":2},{"id":8848360,"accession":"0001209191-15-061938","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-15-061938","line_url":"/filing/0001209191-15-061938#line-3","is_derivative":false,"issuer_cik":"0001290149","issuer_name":"ProNAi Therapeutics Inc","issuer_ticker":"DNAI","issuer_name_source":null,"issuer_url":"/issuer/0001290149","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":220000.0,"shares_display":"220,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":3740000.0,"total_display":"3,740,000.00","total_whole":"3,740,000","shares_owned_after":2186195.0,"shares_owned_after_display":"2,186,195","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-07-21","filed_date":"2015-07-21","scope":"insider"},{"id":8782859,"accession":"0001192482-15-000206","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001192482-15-000206","line_url":"/filing/0001192482-15-000206#line-5","is_derivative":false,"issuer_cik":"0001018534","issuer_name":"COLLEGIUM PHARMACEUTICAL, INC","issuer_ticker":"COLL","issuer_name_source":null,"issuer_url":"/issuer/0001018534","owner_cik":null,"owner_name":"Frazier Healthcare VI, L.P.; FHM VI, L.L.C.; Every Nathan R; FHM VI, L.P.; Topper James N; Naini Nader J; FRAZIER ALAN D","owner_display_name":"Frazier Healthcare VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":1800000.0,"total_display":"1,800,000.00","total_whole":"1,800,000","shares_owned_after":1887332.0,"shares_owned_after_display":"1,887,332","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-12","filed_date":"2015-05-14","scope":"insider"},{"id":5984853,"accession":"0001209191-09-011948","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-011948","line_url":"/filing/0001209191-09-011948#line-3","is_derivative":false,"issuer_cik":"0000920465","issuer_name":"LA JOLLA PHARMACEUTICAL CO","issuer_ticker":"LJPC","issuer_name_source":null,"issuer_url":"/issuer/0000920465","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2756711.0,"shares_display":"2,756,711","price_per_share":0.0562,"price_display":"0.06","price_state":"stated","total_value":154927.1582,"total_display":"154,927.16","total_whole":"154,927","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-02-26","filed_date":"2009-02-26","scope":"insider"},{"id":5984851,"accession":"0001209191-09-011948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-011948","line_url":"/filing/0001209191-09-011948#line-2","is_derivative":false,"issuer_cik":"0000920465","issuer_name":"LA JOLLA PHARMACEUTICAL CO","issuer_ticker":"LJPC","issuer_name_source":null,"issuer_url":"/issuer/0000920465","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1454000.0,"shares_display":"1,454,000","price_per_share":0.0633,"price_display":"0.06","price_state":"stated","total_value":92038.2,"total_display":"92,038.20","total_whole":"92,038","shares_owned_after":2756711.0,"shares_owned_after_display":"2,756,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-02-25","filed_date":"2009-02-26","scope":"insider"},{"id":5984847,"accession":"0001209191-09-011948","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-011948","line_url":"/filing/0001209191-09-011948#line-1","is_derivative":false,"issuer_cik":"0000920465","issuer_name":"LA JOLLA PHARMACEUTICAL CO","issuer_ticker":"LJPC","issuer_name_source":null,"issuer_url":"/issuer/0000920465","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1662000.0,"shares_display":"1,662,000","price_per_share":0.0727,"price_display":"0.07","price_state":"stated","total_value":120827.4,"total_display":"120,827.40","total_whole":"120,827","shares_owned_after":4210711.0,"shares_owned_after_display":"4,210,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-02-24","filed_date":"2009-02-26","scope":"insider"},{"id":3806917,"accession":"0001144204-08-014371","txn_seq":30,"anchor":"line-30","filing_url":"/filing/0001144204-08-014371","line_url":"/filing/0001144204-08-014371","is_derivative":false,"issuer_cik":"0001178879","issuer_name":"AMICUS THERAPEUTICS INC","issuer_ticker":"FOLD","issuer_name_source":null,"issuer_url":"/issuer/0001178879","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":760.0,"shares_display":"760","price_per_share":10.0675,"price_display":"10.07","price_state":"stated","total_value":7651.3,"total_display":"7,651.30","total_whole":"7,651","shares_owned_after":915764.0,"shares_owned_after_display":"915,764","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-10","filed_date":"2008-03-10","scope":"insider","n_lines":5},{"id":3484205,"accession":"0001144204-08-014372","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001144204-08-014372","line_url":"/filing/0001144204-08-014372#line-17","is_derivative":false,"issuer_cik":"0001178879","issuer_name":"AMICUS THERAPEUTICS INC","issuer_ticker":"FOLD","issuer_name_source":null,"issuer_url":"/issuer/0001178879","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1400.0,"shares_display":"1,400","price_per_share":10.23,"price_display":"10.23","price_state":"stated","total_value":14322.0,"total_display":"14,322.00","total_whole":"14,322","shares_owned_after":919364.0,"shares_owned_after_display":"919,364","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-10","filed_date":"2008-03-10","scope":"insider"},{"id":3484202,"accession":"0001144204-08-014372","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001144204-08-014372","line_url":"/filing/0001144204-08-014372#line-16","is_derivative":false,"issuer_cik":"0001178879","issuer_name":"AMICUS THERAPEUTICS INC","issuer_ticker":"FOLD","issuer_name_source":null,"issuer_url":"/issuer/0001178879","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1400.0,"shares_display":"1,400","price_per_share":10.2,"price_display":"10.20","price_state":"stated","total_value":14280.0,"total_display":"14,280.00","total_whole":"14,280","shares_owned_after":917424.0,"shares_owned_after_display":"917,424","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-10","filed_date":"2008-03-10","scope":"insider"},{"id":3484199,"accession":"0001144204-08-014372","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001144204-08-014372","line_url":"/filing/0001144204-08-014372#line-15","is_derivative":false,"issuer_cik":"0001178879","issuer_name":"AMICUS THERAPEUTICS INC","issuer_ticker":"FOLD","issuer_name_source":null,"issuer_url":"/issuer/0001178879","owner_cik":"0001341382","owner_name":"Topper James N","owner_display_name":"Topper James N","owner_url":"/insider/0001341382","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":368.0,"shares_display":"368","price_per_share":10.5,"price_display":"10.50","price_state":"stated","total_value":3864.0,"total_display":"3,864.00","total_whole":"3,864","shares_owned_after":920664.0,"shares_owned_after_display":"920,664","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-10","filed_date":"2008-03-10","scope":"insider"}],"collapsed":true,"next_cursor":"2008-03-10|3484199","ledger_fault":false,"count":{"value":953,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":949,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":953},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001776111","name":"MBX Biosciences, Inc.","url":"/issuer/0001776111","role":"Ten percent owner","n_filings":2,"first_seen":"2024-09-17","last_seen":"2025-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001936258","name":"NewAmsterdam Pharma Co N.V.","url":"/issuer/0001936258","role":"Director","n_filings":8,"first_seen":"2024-03-28","last_seen":"2025-09-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001783183","name":"Phathom Pharmaceuticals, Inc.","url":"/issuer/0001783183","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2019-10-30","last_seen":"2025-05-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001626199","name":"ALPINE IMMUNE SCIENCES, INC.","url":"/issuer/0001626199","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2019-01-22","last_seen":"2024-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001888012","name":"HilleVax, Inc.","url":"/issuer/0001888012","role":"Ten percent owner","n_filings":2,"first_seen":"2022-05-03","last_seen":"2024-04-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Ten percent owner","n_filings":3,"first_seen":"2020-02-06","last_seen":"2023-10-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001828326","name":"Frazier Lifesciences Acquisition Corp","url":"/issuer/0001828326","role":"Director, Officer (Chief Executive Officer)","n_filings":1,"first_seen":"2020-12-11","last_seen":"2020-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001819790","name":"Tarsus Pharmaceuticals, Inc.","url":"/issuer/0001819790","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-20","last_seen":"2020-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001787297","name":"Passage BIO, Inc.","url":"/issuer/0001787297","role":"Ten percent owner","n_filings":1,"first_seen":"2020-03-03","last_seen":"2020-03-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001724344","name":"Entasis Therapeutics Holdings Inc.","url":"/issuer/0001724344","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2018-10-02","last_seen":"2020-01-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001759425","name":"Mirum Pharmaceuticals, Inc.","url":"/issuer/0001759425","role":"Ten percent owner","n_filings":1,"first_seen":"2019-07-24","last_seen":"2019-07-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2018-06-26","last_seen":"2018-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001624658","name":"Allena Pharmaceuticals, Inc.","url":"/issuer/0001624658","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2017-11-06","last_seen":"2017-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001290149","name":"Sierra Oncology, Inc.","url":"/issuer/0001290149","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2015-07-21","last_seen":"2017-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001370053","name":"ANAPTYSBIO INC","url":"/issuer/0001370053","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2017-01-31","last_seen":"2017-01-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001267565","name":"COLLEGIUM PHARMACEUTICAL, INC","url":"/issuer/0001267565","role":"Ten percent owner","n_filings":1,"first_seen":"2015-05-14","last_seen":"2015-05-14"},{"type":"issuer","type_label":"ISSUER","cik":"0000920465","name":"LA JOLLA PHARMACEUTICAL CO","url":"/issuer/0000920465","role":"Director","n_filings":3,"first_seen":"2005-12-14","last_seen":"2009-02-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001178879","name":"AMICUS THERAPEUTICS INC","url":"/issuer/0001178879","role":"Director, Ten percent owner","n_filings":38,"first_seen":"2007-06-29","last_seen":"2008-03-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001341382","retrieved_at":"2026-08-25T00:15:14+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}